THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

Ivry-sur-Seine – France, October 20, 2026, 7:30 AM CET

MERGER CONTROL CLEARANCE FROM THE EUROPEAN COMMISSION OF
THE TAKEOVER BID INITIATED BY EP GROUP

  • Merger control clearance obtained by the European Commission
  • Closing of the Offer expected beginning of November 2026

Fnac Darty and EP FR HOLDCo, a company controlled by EP Group and set up for the purposes of the proposed public tender offer for the outstanding shares and OCEANEs of Fnac Darty (the “Offer”) announce that they have received the merger control clearance from the European Commission for the planned acquisition of Fnac Darty.

As a result of the receipt of this decision, which constitutes the last expected approval of the transaction, the French Financial markets authority (Autorité des marchés financiers – AMF) will announce in the coming days the final timetable for the Offer, and in particular closing date of the tender Offer.

Terms and conditions of the Offer
The Offer price is €35 per share following payment on June 5, 2026 of the €1.0 dividend for the 2025 financial year, and €81.161 per OCEANE.

The Offer was approved on May 7, 2026 by the AMF, which granted its visa on the offer document of EP FR HOLDCo under number 26-128, and on Fnac Darty’s response document under number 26-129.

The Board of Directors of Fnac Darty, on the recommendation of the Ad Hoc Committee, has issued a favorable opinion on the Offer detailed in the response document of Fnac Darty.

Ledouble, acting as an independent expert, has issued a report stating that the financial conditions of the Offer are fair for Fnac Darty’s shareholders and OCEANE holders.

The documentation linked to the Offer is available on Fnac Darty’s website in the dedicated section (https://www.fnacdarty.com/en/group/investors/projet-doffre-publique-dachat-de-ep-group/) as well as on the AMF website (www.amf-france.org).

        

Disclaimer
This press release has been prepared for informational purposes only. It does not constitute an offer to buy or a solicitation for the sale of Fnac Darty shares in any country, including France. The dissemination, publication or distribution of this press release may be subject to specific regulations or restrictions in certain countries. Accordingly, persons in possession of this notice are required to inform themselves of any local restrictions that may apply and to comply with them. Fnac Darty excludes any liability in the event of violation of applicable legal restrictions by any person.

About Fnac Darty

Fnac Darty is a European leader in omnichannel retail, a leading player in the sale of consumer electronics, household appliances, cultural and leisure goods. Present in 15 countries, mainly in France, Italy, Belgium, Portugal, Spain and Switzerland, it has nearly 30,000 employees and a multi-format network of around 1,500 stores, with strong positions on the web and a growing number of subscribers to its services. In 2025, the Group recorded sales of more than €10 billion. With Beyond everyday, its strategic plan for 2030, Fnac Darty is continuing its expansion in Europe and deepening its model based on omnichannel, services and circularity.
For more information: www.fnacdarty.com

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschere – Head of Corporate Communications – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71


1 Assuming an interest period starting on March 23, 2026 and ending on November 12, 2026, as illustrative settlement date of the initial acceptance period of the offer.

Attachment

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

Ivry-sur-Seine – France, October 20, 2026, 7:30 AM CET

MERGER CONTROL CLEARANCE FROM THE EUROPEAN COMMISSION OF
THE TAKEOVER BID INITIATED BY EP GROUP

  • Merger control clearance obtained by the European Commission
  • Closing of the Offer expected beginning of November 2026

Fnac Darty and EP FR HOLDCo, a company controlled by EP Group and set up for the purposes of the proposed public tender offer for the outstanding shares and OCEANEs of Fnac Darty (the “Offer”) announce that they have received the merger control clearance from the European Commission for the planned acquisition of Fnac Darty.

As a result of the receipt of this decision, which constitutes the last expected approval of the transaction, the French Financial markets authority (Autorité des marchés financiers – AMF) will announce in the coming days the final timetable for the Offer, and in particular closing date of the tender Offer.

Terms and conditions of the Offer
The Offer price is €35 per share following payment on June 5, 2026 of the €1.0 dividend for the 2025 financial year, and €81.161 per OCEANE.

The Offer was approved on May 7, 2026 by the AMF, which granted its visa on the offer document of EP FR HOLDCo under number 26-128, and on Fnac Darty’s response document under number 26-129.

The Board of Directors of Fnac Darty, on the recommendation of the Ad Hoc Committee, has issued a favorable opinion on the Offer detailed in the response document of Fnac Darty.

Ledouble, acting as an independent expert, has issued a report stating that the financial conditions of the Offer are fair for Fnac Darty’s shareholders and OCEANE holders.

The documentation linked to the Offer is available on Fnac Darty’s website in the dedicated section (https://www.fnacdarty.com/en/group/investors/projet-doffre-publique-dachat-de-ep-group/) as well as on the AMF website (www.amf-france.org).

        

Disclaimer
This press release has been prepared for informational purposes only. It does not constitute an offer to buy or a solicitation for the sale of Fnac Darty shares in any country, including France. The dissemination, publication or distribution of this press release may be subject to specific regulations or restrictions in certain countries. Accordingly, persons in possession of this notice are required to inform themselves of any local restrictions that may apply and to comply with them. Fnac Darty excludes any liability in the event of violation of applicable legal restrictions by any person.

About Fnac Darty

Fnac Darty is a European leader in omnichannel retail, a leading player in the sale of consumer electronics, household appliances, cultural and leisure goods. Present in 15 countries, mainly in France, Italy, Belgium, Portugal, Spain and Switzerland, it has nearly 30,000 employees and a multi-format network of around 1,500 stores, with strong positions on the web and a growing number of subscribers to its services. In 2025, the Group recorded sales of more than €10 billion. With Beyond everyday, its strategic plan for 2030, Fnac Darty is continuing its expansion in Europe and deepening its model based on omnichannel, services and circularity.
For more information: www.fnacdarty.com

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschere – Head of Corporate Communications – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71


1 Assuming an interest period starting on March 23, 2026 and ending on November 12, 2026, as illustrative settlement date of the initial acceptance period of the offer.

Attachment

  •  Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates

Allschwil, Switzerland, October 20, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”

Fosmanogepix data presented at IDWeek 2026
– Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections
Presenting author: L. E. Hastings
Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas
Date & time: Friday, October 23, 2026, 10:42-10:54 am
Location: 201
   
– Presentation: Activity of manogepix against Candida auris isolates from the United States
Presenting author: M. Winkler
Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Friday, October 23, 2026, 4:15-4:30 pm
Location: 103 AB
   
– Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-18: Activity of manogepix against mold isolates across geographic regions
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Isavuconazole data presented at IDWeek 2026
– Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022]
Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:30-12:35 pm
Location: RF Arena 1
   
– Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
Presenting author: V. Thiruvadi
Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Virtual Presentation
   
– Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey
Presenting author: C. Lan
Co-authors: H. A. Jamal, M. Johnson, S. Vora
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center
Presenting author: W. Monier Texidor
Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia
Presenting author: I. Ramirez
Co-author: C. Ruiz
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Virtual presentation
   
– Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data
Presenting author: M. V. Batista
Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients
Presenting author: M. A. Colaluca
Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis
Presenting author: C. A. Gentry
Co-authors: J. J. Farha, S. Thind, R. Williams, II
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation
Presenting author: F. Herrera
Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

 

Ceftobiprole data presented at IDWeek 2026
–  Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches
Presenting author: A. Tanudra
Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval
Presenting author: R. E. Mendes
Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections
Presenting author: K. B. Larson
Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

For further information please visit www.idweek.org. 

The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company.

For Cresemba® (isavuconazonium sulfate)1 full U.S. prescribing information, please visit: https://www.astellas.us/docs/cresemba.pdf 

For ZEVTERA® (ceftobiprole medocaril sodium)2 full U.S. prescribing information, please visit: https://www.zevtera.com/pi 

Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com 
investor_relations@basilea.com 

This press release can be downloaded from www.basilea.com. 

References

  1. Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S.
  2. Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S.

Attachment

  •  Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates

Allschwil, Switzerland, October 20, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”

Fosmanogepix data presented at IDWeek 2026
– Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections
Presenting author: L. E. Hastings
Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas
Date & time: Friday, October 23, 2026, 10:42-10:54 am
Location: 201
   
– Presentation: Activity of manogepix against Candida auris isolates from the United States
Presenting author: M. Winkler
Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Friday, October 23, 2026, 4:15-4:30 pm
Location: 103 AB
   
– Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-18: Activity of manogepix against mold isolates across geographic regions
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Isavuconazole data presented at IDWeek 2026
– Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022]
Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:30-12:35 pm
Location: RF Arena 1
   
– Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
Presenting author: V. Thiruvadi
Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Virtual Presentation
   
– Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey
Presenting author: C. Lan
Co-authors: H. A. Jamal, M. Johnson, S. Vora
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center
Presenting author: W. Monier Texidor
Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia
Presenting author: I. Ramirez
Co-author: C. Ruiz
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Virtual presentation
   
– Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data
Presenting author: M. V. Batista
Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients
Presenting author: M. A. Colaluca
Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis
Presenting author: C. A. Gentry
Co-authors: J. J. Farha, S. Thind, R. Williams, II
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation
Presenting author: F. Herrera
Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

 

Ceftobiprole data presented at IDWeek 2026
–  Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches
Presenting author: A. Tanudra
Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval
Presenting author: R. E. Mendes
Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C
   
– Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections
Presenting author: K. B. Larson
Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

For further information please visit www.idweek.org. 

The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company.

For Cresemba® (isavuconazonium sulfate)1 full U.S. prescribing information, please visit: https://www.astellas.us/docs/cresemba.pdf 

For ZEVTERA® (ceftobiprole medocaril sodium)2 full U.S. prescribing information, please visit: https://www.zevtera.com/pi 

Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com 
investor_relations@basilea.com 

This press release can be downloaded from www.basilea.com. 

References

  1. Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S.
  2. Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S.

Attachment

Coop Pank AS unaudited financial results for Q3 2026

By the end of Q3 2026, Coop Pank had 240,600 customers, an increase of 5,000 (+2%) during the quarter and 19,000 (+9%) over the year. The bank had 113,900 active customers, an increase of 1,900 (+1.7%) during the quarter and 8,000 (+8%) over the year.

In Q3 2026, the volume of deposits at Coop Pank increased by EUR 131 million (+6%) to reach EUR 2.32 billion. Deposits from private customers increased by EUR 20 million: demand deposits decreased by EUR 6 million and term deposits increased by EUR 26 million. Deposits from domestic business customers increased by EUR 51 million: demand deposits increased by EUR 106 million, while term deposits decreased by EUR 55 million. Deposits raised through platforms increased by EUR 60 million.

Compared with Q3 2025, the volume of Coop Pank’s deposits increased by EUR 408 million (+21%). In Q3 2026, the bank’s cost of funding was 2.1%, compared with 2.3% in the same period last year.

In Q3 2026, Coop Pank’s net loan portfolio increased by EUR 68 million (+3%) to reach EUR 2.3 billion. During the quarter, the strongest growth was recorded in the business loan portfolio, which increased by EUR 33 million (+3%). The home loan portfolio increased by EUR 32 million (+4%), the leasing portfolio increased by EUR 1 million (+1%), and the consumer finance portfolio increased by EUR 3 million (+2%). Compared with Q3 2025, Coop Pank’s total loan portfolio increased by EUR 278 million (+14%). 

In Q3 2026, overdue loan portfolio of Coop Pank was at the level of 2%. A year ago, overdue loan portfolio was at the level of 2.3%.

Impairment costs of financial assets amounted to EUR 0.4 million in Q3 2026, EUR 1 million less than in the previous quarter and EUR 0.3 million less than in Q3 2025.

Coop Pank’s net income amounted to EUR 23.8 million in Q3 2026, increasing by 7% compared with the previous quarter and by 22% compared with Q3 2025. Operating expenses amounted to EUR 12.5 million in Q3 2026, increasing by 13% compared with the previous quarter and by 19% compared with Q3 2025.

In Q3 2026, Coop Pank’s net profit amounted to EUR 9.1 million, an increase of 10% compared with the previous quarter and an increase of 30% compared with Q3 2025. In Q3 2026, the bank’s cost-to-income ratio was 52% and its return on equity was 14.6%.

As of 30 September 2026, Coop Pank had 31,5 thousand shareholders.

Comment on the financial results by Arko Kurtmann, Chairman of the Management Board of Coop Pank:

“The third quarter confirmed that Coop Pank’s growth remains profitable. Our loan portfolio increased by EUR 68 million during the quarter, while net profit rose by 30% year on year. Profit growth was driven by higher lending volumes and the strong quality of our loan portfolio, with the rise in Euribor also supporting our results. We are making good progress towards our strategic target of achieving annual net profit of more than EUR 60 million by 2030.

Coop Pank remains a growth bank, but our financial performance and targets also provide grounds for viewing Coop Pank shares as a dividend investment at their current price level. For investors, this offers an opportunity to earn dividend income while also benefiting from the bank’s continued growth.

During the third quarter, the City of Tallinn sold its stake of approximately 3% in Coop Pank. Strong demand for the shares demonstrated growing confidence in the bank, particularly among professional investors. The number of investors holding more than 100,000 Coop Pank shares also increased. Professional investors conduct thorough analyses of banks, making their growing interest an important vote of confidence in both our performance to date and our future growth plans.

To support the bank’s continued growth, we updated our European Medium Term Note and Covered Bond Programme in September. We doubled the programme limit to EUR 1.5 billion and expanded the range of instruments to include unsecured senior notes and Tier 2 subordinated notes alongside covered bonds, providing us with greater flexibility in our funding. As part of our capital management activities, we also continued repurchasing shares under the previously approved share buyback programme.

Since September, the partnership between Coop Pank and Coop stores has brought significant additional benefits to our customers in their everyday lives, particularly in Harju County. With Prisma stores joining Coop, Coop’s market share in Tallinn will increase from 5% to 17%, significantly expanding the number of people who have a Coop store close to home. Customers with Coop Pank’s Useful and Unlimited plans can also earn cashback at Prisma stores as they gradually transition to the Coop brand. This makes banking with Coop Pank more rewarding for customers shopping in the capital.

At the same time, we have strengthened our position in everyday banking and expanded our offering for customers who travel frequently and expect more comprehensive insurance cover from their bank. In the second quarter, we launched the Unlimited plan, followed by the Platinum credit card in early October, marking our entry into the premium credit card segment. From November, retail banking will be led by Moonika Maaring, who joins the Management Board.

As a domestic bank, we are also committed to contributing to Estonian society. In the third quarter, we signed a new three-year partnership agreement with the Estonian Volleyball Federation to support Estonian volleyball and youth sport, helping to make sporting opportunities more accessible across the country.

Our third-quarter results give us confidence to continue pursuing our chosen strategy. Our ambition is to grow faster than the Estonian banking market, strengthen our position as a domestic bank and create increasing value for both our customers and shareholders.”

Income statement, in th. of euros Q3 2026 Q2 2026 Q3 2025 9M 2026 9M 2025
Net interest income 22 737 20 781 18 299 63 061 54 231
Net fee and commission income 876 1 141 1 100 3 102 3 421
Net other income 150 366 143 703 745
Total net income 23 763 22 288 19 542 66 866 58 397
Payroll expenses -7 664 -6 188 -6 472 -20 248 -17 968
Marketing expenses -497 -465 -370 -1 408 -1 182
Rental and office expenses, depr. of tangible assets -854 -899 -683 -2 639 -2 267
IT expenses and depr. of intangible assets -2 177 -2 115 -1 903 -6 234 -5 240
Other operating expenses -1 274 -1 391 -1 031 -3 960 -3 414
Total operating expenses -12 467 -11 060 -10 459 -34 489 -30 070
Net profit before impairment losses 11 296 11 228 9 083 32 376 28 327
Impairment costs on financial assets -391 -1 419 -664 -2 185 -2 257
Net profit before income tax 10 905 9 809 8 419 30 191 26 070
Income tax expenses -1 828 -1 587 -1 448 -4 586 -4 537
Net profit for the period 9 077 8 222 6 971 25 605 21 533
           
Earnings per share, eur 0,09 0,08 0,07 0,25 0,21
Diluted earnings per share, eur 0,08 0,08 0,07 0,24 0,20

Statement of financial position, in th. of euros 30.09.2026 30.06.2026 31.12.2025 30.09.2025
Cash and cash equivalents 533 997 474 292 488 717 416 496
Debt securities 96 289 96 299 63 023 52 647
Loans to customers 2 301 403 2 233 610 2 114 091 2 023 349
Other assets 33 961 33 354 37 163 39 443
Total assets 2 965 649 2 837 555 2 702 994 2 531 934
Customer deposits and loans received 2 368 562 2 247 677 2 124 520 1 957 852
Debt securities issued 246 876 249 609 255 203 254 676
Other liabilities 25 640 21 665 25 580 28 752
Subordinated debt 72 941 73 262 63 148 63 348
Total liabilities 2 714 018 2 592 213 2 468 451 2 304 629
Equity 251 631 245 342 234 543 227 305
Total liabilities and equity 2 965 649 2 837 555 2 702 994 2 531 934

Coop Pank’s reports are available at: https://www.cooppank.ee/en/investor/reporting.

Coop Pank will host a webinar to present its financial results for the third quarter of 2026 on 20 October 2026 at 9:30 a.m. The webinar can be viewed at https://youtube.com/live/2Z970dozLMM.

During the webinar, participants will be able to submit questions via the Slido platform: https://app.sli.do/event/tTcESCbYM96z9kgmMVYSGM.

The webinar will be recorded and published on Coop Pank’s website and YouTube account.

Coop Pank is one of the five universal banks operating in Estonia and is backed by Estonian capital. The Bank serves 240,600 daily banking customers. Coop Pank’s strategy is to leverage the synergies between the retail business and banking to bring everyday banking services closer to where people live. The Bank’s strategic shareholder is Coop Eesti, Estonia’s domestic retail chain, comprising over 330 stores.

Additional information:
Paavo Truu
CFO
Phone: +372 516 0231
E-mail: paavo.truu@cooppank.ee

Attachments

Coop Pank AS unaudited financial results for Q3 2026

By the end of Q3 2026, Coop Pank had 240,600 customers, an increase of 5,000 (+2%) during the quarter and 19,000 (+9%) over the year. The bank had 113,900 active customers, an increase of 1,900 (+1.7%) during the quarter and 8,000 (+8%) over the year.

In Q3 2026, the volume of deposits at Coop Pank increased by EUR 131 million (+6%) to reach EUR 2.32 billion. Deposits from private customers increased by EUR 20 million: demand deposits decreased by EUR 6 million and term deposits increased by EUR 26 million. Deposits from domestic business customers increased by EUR 51 million: demand deposits increased by EUR 106 million, while term deposits decreased by EUR 55 million. Deposits raised through platforms increased by EUR 60 million.

Compared with Q3 2025, the volume of Coop Pank’s deposits increased by EUR 408 million (+21%). In Q3 2026, the bank’s cost of funding was 2.1%, compared with 2.3% in the same period last year.

In Q3 2026, Coop Pank’s net loan portfolio increased by EUR 68 million (+3%) to reach EUR 2.3 billion. During the quarter, the strongest growth was recorded in the business loan portfolio, which increased by EUR 33 million (+3%). The home loan portfolio increased by EUR 32 million (+4%), the leasing portfolio increased by EUR 1 million (+1%), and the consumer finance portfolio increased by EUR 3 million (+2%). Compared with Q3 2025, Coop Pank’s total loan portfolio increased by EUR 278 million (+14%). 

In Q3 2026, overdue loan portfolio of Coop Pank was at the level of 2%. A year ago, overdue loan portfolio was at the level of 2.3%.

Impairment costs of financial assets amounted to EUR 0.4 million in Q3 2026, EUR 1 million less than in the previous quarter and EUR 0.3 million less than in Q3 2025.

Coop Pank’s net income amounted to EUR 23.8 million in Q3 2026, increasing by 7% compared with the previous quarter and by 22% compared with Q3 2025. Operating expenses amounted to EUR 12.5 million in Q3 2026, increasing by 13% compared with the previous quarter and by 19% compared with Q3 2025.

In Q3 2026, Coop Pank’s net profit amounted to EUR 9.1 million, an increase of 10% compared with the previous quarter and an increase of 30% compared with Q3 2025. In Q3 2026, the bank’s cost-to-income ratio was 52% and its return on equity was 14.6%.

As of 30 September 2026, Coop Pank had 31,5 thousand shareholders.

Comment on the financial results by Arko Kurtmann, Chairman of the Management Board of Coop Pank:

“The third quarter confirmed that Coop Pank’s growth remains profitable. Our loan portfolio increased by EUR 68 million during the quarter, while net profit rose by 30% year on year. Profit growth was driven by higher lending volumes and the strong quality of our loan portfolio, with the rise in Euribor also supporting our results. We are making good progress towards our strategic target of achieving annual net profit of more than EUR 60 million by 2030.

Coop Pank remains a growth bank, but our financial performance and targets also provide grounds for viewing Coop Pank shares as a dividend investment at their current price level. For investors, this offers an opportunity to earn dividend income while also benefiting from the bank’s continued growth.

During the third quarter, the City of Tallinn sold its stake of approximately 3% in Coop Pank. Strong demand for the shares demonstrated growing confidence in the bank, particularly among professional investors. The number of investors holding more than 100,000 Coop Pank shares also increased. Professional investors conduct thorough analyses of banks, making their growing interest an important vote of confidence in both our performance to date and our future growth plans.

To support the bank’s continued growth, we updated our European Medium Term Note and Covered Bond Programme in September. We doubled the programme limit to EUR 1.5 billion and expanded the range of instruments to include unsecured senior notes and Tier 2 subordinated notes alongside covered bonds, providing us with greater flexibility in our funding. As part of our capital management activities, we also continued repurchasing shares under the previously approved share buyback programme.

Since September, the partnership between Coop Pank and Coop stores has brought significant additional benefits to our customers in their everyday lives, particularly in Harju County. With Prisma stores joining Coop, Coop’s market share in Tallinn will increase from 5% to 17%, significantly expanding the number of people who have a Coop store close to home. Customers with Coop Pank’s Useful and Unlimited plans can also earn cashback at Prisma stores as they gradually transition to the Coop brand. This makes banking with Coop Pank more rewarding for customers shopping in the capital.

At the same time, we have strengthened our position in everyday banking and expanded our offering for customers who travel frequently and expect more comprehensive insurance cover from their bank. In the second quarter, we launched the Unlimited plan, followed by the Platinum credit card in early October, marking our entry into the premium credit card segment. From November, retail banking will be led by Moonika Maaring, who joins the Management Board.

As a domestic bank, we are also committed to contributing to Estonian society. In the third quarter, we signed a new three-year partnership agreement with the Estonian Volleyball Federation to support Estonian volleyball and youth sport, helping to make sporting opportunities more accessible across the country.

Our third-quarter results give us confidence to continue pursuing our chosen strategy. Our ambition is to grow faster than the Estonian banking market, strengthen our position as a domestic bank and create increasing value for both our customers and shareholders.”

Income statement, in th. of euros Q3 2026 Q2 2026 Q3 2025 9M 2026 9M 2025
Net interest income 22 737 20 781 18 299 63 061 54 231
Net fee and commission income 876 1 141 1 100 3 102 3 421
Net other income 150 366 143 703 745
Total net income 23 763 22 288 19 542 66 866 58 397
Payroll expenses -7 664 -6 188 -6 472 -20 248 -17 968
Marketing expenses -497 -465 -370 -1 408 -1 182
Rental and office expenses, depr. of tangible assets -854 -899 -683 -2 639 -2 267
IT expenses and depr. of intangible assets -2 177 -2 115 -1 903 -6 234 -5 240
Other operating expenses -1 274 -1 391 -1 031 -3 960 -3 414
Total operating expenses -12 467 -11 060 -10 459 -34 489 -30 070
Net profit before impairment losses 11 296 11 228 9 083 32 376 28 327
Impairment costs on financial assets -391 -1 419 -664 -2 185 -2 257
Net profit before income tax 10 905 9 809 8 419 30 191 26 070
Income tax expenses -1 828 -1 587 -1 448 -4 586 -4 537
Net profit for the period 9 077 8 222 6 971 25 605 21 533
           
Earnings per share, eur 0,09 0,08 0,07 0,25 0,21
Diluted earnings per share, eur 0,08 0,08 0,07 0,24 0,20

Statement of financial position, in th. of euros 30.09.2026 30.06.2026 31.12.2025 30.09.2025
Cash and cash equivalents 533 997 474 292 488 717 416 496
Debt securities 96 289 96 299 63 023 52 647
Loans to customers 2 301 403 2 233 610 2 114 091 2 023 349
Other assets 33 961 33 354 37 163 39 443
Total assets 2 965 649 2 837 555 2 702 994 2 531 934
Customer deposits and loans received 2 368 562 2 247 677 2 124 520 1 957 852
Debt securities issued 246 876 249 609 255 203 254 676
Other liabilities 25 640 21 665 25 580 28 752
Subordinated debt 72 941 73 262 63 148 63 348
Total liabilities 2 714 018 2 592 213 2 468 451 2 304 629
Equity 251 631 245 342 234 543 227 305
Total liabilities and equity 2 965 649 2 837 555 2 702 994 2 531 934

Coop Pank’s reports are available at: https://www.cooppank.ee/en/investor/reporting.

Coop Pank will host a webinar to present its financial results for the third quarter of 2026 on 20 October 2026 at 9:30 a.m. The webinar can be viewed at https://youtube.com/live/2Z970dozLMM.

During the webinar, participants will be able to submit questions via the Slido platform: https://app.sli.do/event/tTcESCbYM96z9kgmMVYSGM.

The webinar will be recorded and published on Coop Pank’s website and YouTube account.

Coop Pank is one of the five universal banks operating in Estonia and is backed by Estonian capital. The Bank serves 240,600 daily banking customers. Coop Pank’s strategy is to leverage the synergies between the retail business and banking to bring everyday banking services closer to where people live. The Bank’s strategic shareholder is Coop Eesti, Estonia’s domestic retail chain, comprising over 330 stores.

Additional information:
Paavo Truu
CFO
Phone: +372 516 0231
E-mail: paavo.truu@cooppank.ee

Attachments

Key developments in Q3 2026:

  • Revenue and other income of NOK 150 million in the third quarter of 2026, 40% lower compared to the same period last year (20% lower excluding the deconsolidated business). Year-to-date revenue and other income of NOK 701 million, up 4% compared to the first nine months of 2025;
  • EBITDA of NOK -83 million in the third quarter of 2026, compared to NOK -116 million in the same period last year. Year-to-date EBITDA of NOK -184 million, compared to NOK -519 million in the first nine months of 2025; and
  • Exited the quarter with order backlog consisting of firm purchase orders of NOK 508 million.

“The third quarter is the first quarter to reflect most of our significant cost reductions, with an annualized cost base around 50% below 2024 level,” says Morten Holum, CEO of Hexagon Purus. We expect a volume uplift in the fourth quarter, and most of the expected revenue is covered by firm orders. Together with the lower cost base, this provides an opportunity to approach underlying EBITDA break-even at Group level for the first time. At the same time, we are in dialogue with key stakeholders on a financial restructuring to address the Company’s debt burden and establish a more sustainable capital structure.”

Hexagon Purus Q3 2026 consolidated financials

In the third quarter of 2026, Hexagon Purus (“the Company” or “the Group”) generated revenue and other income of NOK 150 million, down 40% compared to the corresponding period in 2025. Excluding the deconsolidated business which occurred in the first quarter of 2026, the decrease in revenue was 20% and primarily driven by lower activity within hydrogen infrastructure, transit bus and industrial gas applications, partly offset by higher activity in battery electric mobility and rail applications.

Total operating expenses in the third quarter of 2026 amounted to NOK 233 (368) million, leading to an operating profit before depreciation (EBITDA) of NOK -83 (-116) million.

Total assets at the end of the third quarter of 2026 amounted to NOK 2,623 (3,988) million. Property, plant and equipment totaled NOK 589 (1,102) million at quarter-end. Right-of-use assets amounted to NOK 299 (499) million at quarter-end, while intangible assets ended at NOK 563 (674) million.

Inventory amounted to NOK 360 (758) million at the end of the third quarter of 2026 down NOK 22 million from the second quarter of 2026. Trade receivables stood at NOK 198 (234) million at quarter-end, up from NOK 180 million in the second quarter of 2026, mainly reflecting the higher revenue in BVI in the quarter.

Total equity amounted to NOK -224 (1,054) million at the end of the third quarter of 2026. Management and the Board are holding discussions with key stakeholders on a financial restructuring, including measures relating to the outstanding convertible bonds, with the objective of reducing the Company’s debt burden and restoring positive consolidated equity.

Non-current liabilities amounted to NOK 2,438 (2,298) million at the end of the third quarter, of which NOK 2,031 (1,754) million comprised interest-bearing debt, primarily related to the two outstanding convertible bonds, maturing in Q1 2028 and Q1 2029, respectively. Total current liabilities stood at NOK 409 (636) million at the end of the third quarter of 2026, up from NOK 383 million in the second quarter. The increase was driven by trade payables of NOK 134 (179) million and contract liabilities of NOK 71 million, up from NOK 36 million in the second quarter, primarily reflecting customer pre-payments.

Net cash flow from operating activities in the third quarter of 2026 amounted to NOK -67 (-115) million. The quarter included a favorable working capital development of NOK 64 (-26) million, driven by an increase in trade payables and customer pre-payments of NOK 60 million and lower inventory (NOK 22 million), partly offset by higher trade receivables (NOK 18 million).

Net cash flow from investing activities amounted to NOK 9 (-34) million in the third quarter of 2026. Capital expenditures in the quarter ended at NOK -1 (-14) million. Capitalized product development was NOK -2 (-16) million, and primarily reflects targeted investment in a small number of next-generation product and technology initiatives. Net cash flow from financing in the third quarter of 2026 was NOK -19 (-15) million. Cash and cash equivalents ended at NOK 220 (360) million as of the third quarter of 2026. 

Hydrogen Mobility and Infrastructure (HMI)

Revenue and other income for the HMI segment amounted to NOK 104 million in the third quarter of 2026, representing a decrease of 55% year-over-year. Excluding the divested U.S. business, which occurred during the first quarter of 2026, segment revenue declined by 38% year-over-year. The underlying revenue development was primarily impacted by lower activity within hydrogen infrastructure, transit bus and industrial gas applications, partly offset by increased revenue from rail applications.

EBITDA for the HMI segment was NOK -34 (-47) million in the third quarter of 2026.

Historical segment financials are made available on www.hexagonpurus.com together with Q3
2026 report and presentation.

Battery Systems and Vehicle Integration (BVI)

Revenue and other income for the BVI segment totaled NOK 35 (13) million in the third quarter of 2026. The year-over-year revenue growth reflects eight vehicle deliveries to Hino and sublease revenue from the Dallas facility.

EBITDA for the BVI segment amounted to NOK -28 (-30) million in the third quarter of 2026. The higher revenue did not translate into improved profitability year-over-year, as the vehicle deliveries in the quarter carried high materials cost from legacy inventory and required additional temporary labour to support the truck builds.

Historical segment financials are made available on www.hexagonpurus.com together with Q3
2026 report and presentation.

Outlook

The Company enters the fourth quarter with most of the expected revenue covered by firm orders and a substantially lower cost base. The anticipated volumes provide an opportunity to approach underlying EBITDA break-even at Group level for the first time, although this remains dependent on completing a demanding delivery schedule at expected margins. Hydrogen distribution deliveries are concentrated in Q4, leaving limited room to absorb delays before year-end.

Recent orders have strengthened visibility into 2027, with the backlog for delivery next year broadly comparable in absolute terms to the following-year backlog at the end of Q3 2025. Supported by the reduced cost base, the Company’s target is to reach EBITDA break-even in the current market environment. Sustained positive EBITDA on a full-year basis will require some increase in order intake, alongside continued cost discipline. Recent datapoints on growth in clean hydrogen production and investments into a heavy-duty transportation ecosystem in parts of Europe are encouraging, but high costs, infrastructure constraints and policy dependence continue to weigh on market development. The Company will continuously assess these conditions and adjust operations, costs or strategic priorities as needed.

Strengthening the Company’s financial position remains a central priority given the Group’s negative consolidated equity and continued cash consumption. Management and the Board are holding discussions with key stakeholders on a financial restructuring to address the Company’s debt burden and establish a sustainable capital structure.

Presentation of the results

Hexagon Purus will present the Q3 2026 results today, 20 October, at 08:30 CEST and the presentation will be broadcast live via https://event.plaii.no/hexagon/2c2953f439.

The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com.

For more information:

Mathias Meidell, Senior Director Finance, Hexagon Purus ASA
Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com

Salman Alam, CFO, Hexagon Purus ASA
Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com

About Hexagon Purus ASA

Hexagon Purus enables zero emission mobility for a cleaner energy future. The company is a world leading provider of hydrogen Type 4 high-pressure cylinders and systems, battery systems and vehicle integration solutions for fuel cell electric and battery electric vehicles. Hexagon Purus’ products are used in a variety of applications including light, medium and heavy-duty vehicles, buses, ground storage, distribution, refueling, maritime and rail.

Learn more at www.hexagonpurus.com and follow @HexagonPurus on X and LinkedIn.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachments

Key developments in Q3 2026:

  • Revenue and other income of NOK 150 million in the third quarter of 2026, 40% lower compared to the same period last year (20% lower excluding the deconsolidated business). Year-to-date revenue and other income of NOK 701 million, up 4% compared to the first nine months of 2025;
  • EBITDA of NOK -83 million in the third quarter of 2026, compared to NOK -116 million in the same period last year. Year-to-date EBITDA of NOK -184 million, compared to NOK -519 million in the first nine months of 2025; and
  • Exited the quarter with order backlog consisting of firm purchase orders of NOK 508 million.

“The third quarter is the first quarter to reflect most of our significant cost reductions, with an annualized cost base around 50% below 2024 level,” says Morten Holum, CEO of Hexagon Purus. We expect a volume uplift in the fourth quarter, and most of the expected revenue is covered by firm orders. Together with the lower cost base, this provides an opportunity to approach underlying EBITDA break-even at Group level for the first time. At the same time, we are in dialogue with key stakeholders on a financial restructuring to address the Company’s debt burden and establish a more sustainable capital structure.”

Hexagon Purus Q3 2026 consolidated financials

In the third quarter of 2026, Hexagon Purus (“the Company” or “the Group”) generated revenue and other income of NOK 150 million, down 40% compared to the corresponding period in 2025. Excluding the deconsolidated business which occurred in the first quarter of 2026, the decrease in revenue was 20% and primarily driven by lower activity within hydrogen infrastructure, transit bus and industrial gas applications, partly offset by higher activity in battery electric mobility and rail applications.

Total operating expenses in the third quarter of 2026 amounted to NOK 233 (368) million, leading to an operating profit before depreciation (EBITDA) of NOK -83 (-116) million.

Total assets at the end of the third quarter of 2026 amounted to NOK 2,623 (3,988) million. Property, plant and equipment totaled NOK 589 (1,102) million at quarter-end. Right-of-use assets amounted to NOK 299 (499) million at quarter-end, while intangible assets ended at NOK 563 (674) million.

Inventory amounted to NOK 360 (758) million at the end of the third quarter of 2026 down NOK 22 million from the second quarter of 2026. Trade receivables stood at NOK 198 (234) million at quarter-end, up from NOK 180 million in the second quarter of 2026, mainly reflecting the higher revenue in BVI in the quarter.

Total equity amounted to NOK -224 (1,054) million at the end of the third quarter of 2026. Management and the Board are holding discussions with key stakeholders on a financial restructuring, including measures relating to the outstanding convertible bonds, with the objective of reducing the Company’s debt burden and restoring positive consolidated equity.

Non-current liabilities amounted to NOK 2,438 (2,298) million at the end of the third quarter, of which NOK 2,031 (1,754) million comprised interest-bearing debt, primarily related to the two outstanding convertible bonds, maturing in Q1 2028 and Q1 2029, respectively. Total current liabilities stood at NOK 409 (636) million at the end of the third quarter of 2026, up from NOK 383 million in the second quarter. The increase was driven by trade payables of NOK 134 (179) million and contract liabilities of NOK 71 million, up from NOK 36 million in the second quarter, primarily reflecting customer pre-payments.

Net cash flow from operating activities in the third quarter of 2026 amounted to NOK -67 (-115) million. The quarter included a favorable working capital development of NOK 64 (-26) million, driven by an increase in trade payables and customer pre-payments of NOK 60 million and lower inventory (NOK 22 million), partly offset by higher trade receivables (NOK 18 million).

Net cash flow from investing activities amounted to NOK 9 (-34) million in the third quarter of 2026. Capital expenditures in the quarter ended at NOK -1 (-14) million. Capitalized product development was NOK -2 (-16) million, and primarily reflects targeted investment in a small number of next-generation product and technology initiatives. Net cash flow from financing in the third quarter of 2026 was NOK -19 (-15) million. Cash and cash equivalents ended at NOK 220 (360) million as of the third quarter of 2026. 

Hydrogen Mobility and Infrastructure (HMI)

Revenue and other income for the HMI segment amounted to NOK 104 million in the third quarter of 2026, representing a decrease of 55% year-over-year. Excluding the divested U.S. business, which occurred during the first quarter of 2026, segment revenue declined by 38% year-over-year. The underlying revenue development was primarily impacted by lower activity within hydrogen infrastructure, transit bus and industrial gas applications, partly offset by increased revenue from rail applications.

EBITDA for the HMI segment was NOK -34 (-47) million in the third quarter of 2026.

Historical segment financials are made available on www.hexagonpurus.com together with Q3
2026 report and presentation.

Battery Systems and Vehicle Integration (BVI)

Revenue and other income for the BVI segment totaled NOK 35 (13) million in the third quarter of 2026. The year-over-year revenue growth reflects eight vehicle deliveries to Hino and sublease revenue from the Dallas facility.

EBITDA for the BVI segment amounted to NOK -28 (-30) million in the third quarter of 2026. The higher revenue did not translate into improved profitability year-over-year, as the vehicle deliveries in the quarter carried high materials cost from legacy inventory and required additional temporary labour to support the truck builds.

Historical segment financials are made available on www.hexagonpurus.com together with Q3
2026 report and presentation.

Outlook

The Company enters the fourth quarter with most of the expected revenue covered by firm orders and a substantially lower cost base. The anticipated volumes provide an opportunity to approach underlying EBITDA break-even at Group level for the first time, although this remains dependent on completing a demanding delivery schedule at expected margins. Hydrogen distribution deliveries are concentrated in Q4, leaving limited room to absorb delays before year-end.

Recent orders have strengthened visibility into 2027, with the backlog for delivery next year broadly comparable in absolute terms to the following-year backlog at the end of Q3 2025. Supported by the reduced cost base, the Company’s target is to reach EBITDA break-even in the current market environment. Sustained positive EBITDA on a full-year basis will require some increase in order intake, alongside continued cost discipline. Recent datapoints on growth in clean hydrogen production and investments into a heavy-duty transportation ecosystem in parts of Europe are encouraging, but high costs, infrastructure constraints and policy dependence continue to weigh on market development. The Company will continuously assess these conditions and adjust operations, costs or strategic priorities as needed.

Strengthening the Company’s financial position remains a central priority given the Group’s negative consolidated equity and continued cash consumption. Management and the Board are holding discussions with key stakeholders on a financial restructuring to address the Company’s debt burden and establish a sustainable capital structure.

Presentation of the results

Hexagon Purus will present the Q3 2026 results today, 20 October, at 08:30 CEST and the presentation will be broadcast live via https://event.plaii.no/hexagon/2c2953f439.

The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com.

For more information:

Mathias Meidell, Senior Director Finance, Hexagon Purus ASA
Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com

Salman Alam, CFO, Hexagon Purus ASA
Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com

About Hexagon Purus ASA

Hexagon Purus enables zero emission mobility for a cleaner energy future. The company is a world leading provider of hydrogen Type 4 high-pressure cylinders and systems, battery systems and vehicle integration solutions for fuel cell electric and battery electric vehicles. Hexagon Purus’ products are used in a variety of applications including light, medium and heavy-duty vehicles, buses, ground storage, distribution, refueling, maritime and rail.

Learn more at www.hexagonpurus.com and follow @HexagonPurus on X and LinkedIn.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachments

For LHV Group, the third quarter of 2026 was characterised by growth in income and profitability, both quarter-on-quarter and year-on-year. The strong result was driven by net interest income and fee income, as well as a larger release of loan impairments.

AS LHV Group generated consolidated net profit of EUR 37.5 million in Q3 2026, which is 52% more than in the previous quarter and 43% more than in the same period last year. Of the subsidiaries, AS LHV Pank earned a net profit of EUR 33.7 million and LHV Bank Ltd EUR 1.4 million. AS LHV Varahaldus earned a net profit of EUR 0.5 million and AS LHV Kindlustus EUR 0.3 million. The return on equity attributable to the shareholders of the Group was 19.3% in Q3.

On a consolidated basis, LHV Group generated total net income of EUR 80.1 million in Q3 2026, which is 1% more than in the previous quarter and 10% more than in the same period last year. Net interest income amounted to EUR 68.8 million (+10% quarter-on-quarter and +24% year-on-year). Growth was supported by the expansion of the loan portfolio and improved margins, with the net interest margin reaching 2.8% (Q2: 2.6%). Net fee and commission income amounted to EUR 16.8 million (+15% quarter-on-quarter and +10% year-on-year). Other income amounted to EUR -5.5 million, mainly reflecting the revaluation of the liquidity portfolio. Portfolio duration is below two years, so the loss unwinds as positions mature and in parallel generates additional interest income booked under net interest income.

Total operating expenses amounted to EUR 43.4 million, remaining at the level of the previous quarter and increasing by 12% year-on-year. Staff costs decreased by 8% quarter-on-quarter to EUR 24.1 million, while IT costs increased by 12% to EUR 5.3 million. The cost/income ratio was 54.2%. Profit before loan impairment amounted to EUR 36.7 million (+4% quarter-on-quarter and +8% year-on-year). A net release of loan impairments of EUR 8.9 million was recognised in Q3. The release came from LHV Pank and was mainly related to the release of a provision for one larger client.

As at the end of September, LHV Group’s consolidated total assets stood at EUR 10.10 billion, up 5% from the end of the previous quarter and 6% year-on-year. The consolidated loan portfolio grew by EUR 183 million, i.e. 3%, to EUR 5.95 billion in Q3 (+14% year-on-year). Deposits increased by EUR 178 million, i.e. 2%, during the quarter to EUR 7.74 billion (+4% year-on-year). The aggregate volume of funds managed by LHV grew by EUR 25 million during the quarter to EUR 1.82 billion (+12% year-on-year). Financial intermediary customers processed 24.2 million payments in Q3, a decrease of 6% compared to the previous quarter and an increase of 18% year-on-year. The number of Group customers increased by nearly 8,000 during the quarter to 723,000.

For the first nine months of the year, LHV Group generated total net income of EUR 232.8 million (+3% year-on-year), of which net interest income accounted for EUR 190.6 million (+9%) and net fee and commission income for EUR 46.1 million (+3%). Expenses grew by 14% to EUR 132.6 million. The net release of loan impairments totalled EUR 1.8 million over the nine months. Net profit amounted to EUR 81.9 million, which is 5% less than a year ago. The return on equity for the nine months was 14.0% (a year ago: 16.1%) and the cost/income ratio 57.0% (a year ago: 51.7%).

The Group’s Common Equity Tier 1 (CET1) ratio stood at 15.3% at the end of Q3, the Tier 1 capital ratio at 17.2% and the total capital adequacy ratio (CAD) at 20.3%. The liquidity coverage ratio (LCR) was 174% and the net stable funding ratio (NSFR) 146%. In August, LHV Group issued EUR 200 million of MREL bonds and EUR 15 million of AT1 bonds.

As at the end of nine months, LHV Group’s net income is falling short of the financial plan by EUR 4.5 million, while net profit exceeds the financial plan by EUR 3.6 million.

Income statement, thousands of euros   Q3 2026 Q2 2026 Q3 2025
Net interest income 68,811 62,480 55,532
Net fee and commission income 16,799 14,643 15,296
Net financial income -5,765 1,170 1,167
Result of the insurance service 219 744 627
Other operating income and expenses 60 -26 39
Total net income   80,124 79,011 72,661
Staff costs -24,072 -26,089 -22,351
Office expenses -807 -713 -730
IT costs -5,300 -4,717 -3,837
Marketing expenses -1,790 -1,059 -1,140
Other operating expenses -11,461 -11,013 -10,705
Total expenses   -43,429 -43,591 -38,763
Profit before loan impairment   36,695 35,420 33,898
Loan impairment 8,892 -5,770 -1,673
Income tax expense -8,053 -4,963 -5,916
Net profit   37,534 24,687 26,309
Minority holding 450 574 606
Profit attributable to shareholders of the parent company 37,084 24,113 25,703
         
Net profit per share, euros 0.11 0.07 0.08
Diluted net profit per share, euros 0.11 0.07 0.08
        
Balance sheet, thousands of euros   Sep 26 Jun 26 Sep 25
Cash and due from banks 3,001,723 2,760,278 3,837,093
Financial assets 1,065,486 1,058,984 402,971
Loans to customers 5,989,915 5,815,325 5,279,528
Loan impairment reserve -38,875 -47,449 -45,277
Trade receivables 41,782 29,241 12,403
Other assets 40,907 35,667 42,980
Total assets   10,100,938 9,652,047 9,529,699
Demand deposits 5,149,077 5,130,731 4,862,458
Term deposits 2,586,258 2,426,535 2,590,440
Loans received 1,232,577 1,021,079 1,048,556
Trade payables and loans received 8,967,911 8,578,345 8,501,454
Accrued expenses and other liabilities 117,143 106,273 84,143
Subordinated debt 222,295 209,215 207,001
Total liabilities   9,307,350 8,893,833 8,792,598
Owners’ equity   793,588 758,214 737,101
incl. minority holding 7,976 7,526 8,456
Total liabilities and owners’ equity   10,100,938 9,652,047 9,529,699

LHV Pank

LHV Pank’s net profit amounted to EUR 33.7 million in Q3 (+39% quarter-on-quarter and +38% year-on-year) and total net income to EUR 57.7 million (-7% quarter-on-quarter and +5% year-on-year). Net interest income grew by 11% quarter-on-quarter to EUR 59.5 million (+22% year-on-year) and net fee and commission income by 14% to EUR 13.5 million (+15% year-on-year). Expenses decreased by 5% quarter-on-quarter to EUR 26.9 million. A net release of loan impairments of EUR 10.4 million was recognised in Q3, significantly affected by the reversal of a provision on one larger corporate loan. The cost/income ratio was 46.6% (Q2: 45.3%) and return on equity 21.6% (Q2: 16.6%).

The quarter-on-quarter decrease in net income was driven by negative net financial income of EUR 10.1 million, which includes the negative effect of the liquidity portfolio and revaluation of intragroup interest rate swaps. The revaluation loss on the liquidity portfolio, which has a duration of less than two years, unwinds as the bonds mature, while the portfolio generates additional net interest income in parallel. The effect of the interest rate swaps is eliminated at the Group level. Excluding this effect, the bank’s net income amounted to EUR 61.8 million and net profit to EUR 37.9 million.

The number of LHV Pank customers increased by nearly 9,000 during the quarter to 517,000. The net loan portfolio grew by EUR 92 million during the quarter to EUR 4.91 billion (+7% year-on-year). Retail loans grew by EUR 64 million and corporate loans by EUR 28 million. The bank’s deposits increased by EUR 192 million during the quarter to EUR 6.42 billion (-3% year-on-year), of which demand deposits increased by EUR 148 million and term deposits by EUR 44 million. The increase was mainly driven by EUR 143 million growth in corporate banking deposits, while platform deposits continued to decline in line with the trend of this year.

In technology, LHV Pank took an important step in Q3 with the launch of LHV.AI, which provides a secure foundation for scaling artificial intelligence and for next-generation services for the bank’s customers. In product development, the bank launched Moneyplan, a feature that gives customers an overview of their saving habits and supports them in building regular saving. In July, the international financial magazine Euromoney recognised the bank as the Best Bank in Estonia for the seventh time. In September, the bank announced its decision to close its customer offices in Tartu and Pärnu. The decision is based on customers’ changing banking habits and the continued decline in visits to physical offices. The bank continues to invest in digital service channels, through which all main banking services are available.

For the first nine months of the year, LHV Pank generated total net income of EUR 174.0 million (+1% year-on-year) and a net profit of EUR 78.2 million (-1% year-on-year). Net income is falling short of the financial plan by EUR 8.2 million (by EUR 2.5 million excluding the revaluation effect of interest rate swaps), while net profit exceeds the plan by EUR 2.3 million (by EUR 8.1 million excluding the revaluation effect). The loan portfolio exceeds the financial plan by EUR 88 million, while deposits are EUR 340 million below plan.

LHV Bank

LHV Bank, operating in the United Kingdom, reported a net profit of EUR 1.4 million in Q3, remaining at the level of the previous quarter and up 38% year-on-year. Total net income grew by 16% quarter-on-quarter to EUR 17.1 million (+31% year-on-year) and net interest income by 10% to EUR 10.5 million (+64% year-on-year). Loan impairment charges of EUR 1.5 million were recognised in the quarter. The cost/income ratio improved to 80.4% (Q2: 85.2%).

The loan portfolio of LHV Bank grew by EUR 87 million, i.e. 9%, during the quarter to EUR 1.03 billion (+56% year-on-year). The pipeline of outstanding loan offers, approved but not yet disbursed, amounted to EUR 145 million. Deposits increased by EUR 119 million during the quarter to EUR 1.51 billion (+50% year-on-year). Direct customer deposits amounted to EUR 323 million at the end of the quarter.

For the first nine months of the year, LHV Bank’s net income grew by 17% to EUR 46.9 million, net interest income by 64% to EUR 29.3 million and net profit by 24% to EUR 4.1 million. Net interest income exceeds the financial plan by EUR 1.2 million. Net income is falling short of the plan by EUR 0.6 million and net profit by EUR 2.2 million, reflecting higher than planned loan impairments and expenses EUR 0.9 million above plan. The loan portfolio is EUR 58 million below plan and deposits are EUR 117 million below plan.

LHV Varahaldus

LHV Varahaldus earned a net profit of EUR 0.5 million in Q3 (Q2: EUR 0.4 million, Q3 2025: EUR 0.8 million). Net income grew by 2% quarter-on-quarter and by 8% year-on-year to EUR 2.5 million.

The aggregate volume of funds grew by EUR 25 million during the quarter to EUR 1.82 billion (+12% year-on-year). In Q3, the pension funds Julge, Ettevõtlik, Rahulik, Tasakaalukas and Indeks returned 1.3%, 2.2%, 0.3%, 1.1% and 1.6% respectively. At the end of the quarter, the number of Pillar II customers making active monthly contributions stood at 104,000.

For the first nine months of the year, LHV Varahaldus’s net income grew by 9% to EUR 7.3 million. Net profit amounted to EUR 0.3 million (a year earlier: EUR 1.4 million), affected by the EUR 1.1 million income tax expense associated with the dividend payment made in March. Net profit exceeds the financial plan by EUR 0.1 million, while fund volumes are EUR 14 million below plan.

LHV Kindlustus

LHV Kindlustus earned a net profit of EUR 0.3 million in Q3 (Q2: EUR 0.8 million, Q3 2025: EUR 0.7 million). Net earned premiums grew by 5% quarter-on-quarter to EUR 11.7 million (+10% year-on-year). The volume of contract premiums written amounted to EUR 11.0 million, which is 6% less than in the previous quarter and 20% more than a year ago.

Gross incurred losses increased by 15% quarter-on-quarter to EUR 8.2 million (+20% year-on-year). The net loss ratio was 72.5% (Q2: 67.9%), the net expense ratio 25.6% (Q2: 25.2%) and the combined ratio 98.1% (Q2: 93.1%). The number of customers increased by nearly 4,000 during the quarter to 246,000 (+8% year-on-year) and the number of insurance contracts stood at 337,000. The quarter was affected by several larger claims in home insurance.

For the first nine months of the year, LHV Kindlustus’s net earned premiums grew by 9% to EUR 33.3 million and gross incurred losses by 20% to EUR 23.6 million. Net profit amounted to EUR 0.4 million (a year earlier: EUR 2.4 million) and the net loss ratio was 74.0%. Net profit is falling short of the financial plan by EUR 1.7 million, mainly due to the high volume of claims at the beginning of the year. The volume of contract premiums written exceeds the financial plan by EUR 0.7 million.

Comment by Mihkel Torim, CEO of LHV Group:

“The third quarter was LHV’s strongest of the year. Net profit rose to EUR 37.5 million and return on equity to 19.3%. Our core business improved: net interest income grew 24% year on year, while costs held at the previous quarter’s level. Profit was also substantially supported by September’s release of an impairment on one large corporate loan and portfolio quality remained strong.

The loan portfolio grew by EUR 183 million in the quarter, almost half of it from LHV Bank in the UK, whose loan book passed one billion euros. The Group’s customer base reached 723,000. In August we raised EUR 200 million of MREL debt to further diversify our funding.

In Estonia we launched Moneyplan, which gives customers an overview of their spending and saving. We also went live with LHV.AI, which lets customers connect their bank account to AI tools. Positive reception of these new products confirms that we are moving in the right direction.”

AS LHV Group reports are available at: https://investor.lhv.ee/en/reports/.

To present the quarterly results, LHV Group will host a virtual investor meeting via Teams. The meeting will take place on 20 October at 11:00 AM EET. The presentation will be held in English. Please register in advance here.

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are used by over 517,000 customers, the II pillar pension funds managed by LHV have 104,000 active customers and LHV Kindlustus protects a total of 246,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises.

Investor Relations
Sten Hans Jakobsoo
Head of Investor Relations and Corporate Development
Email: stenhans.jakobsoo@lhv.ee

Communications
Paul Pihlak
Head of Communications
Email: paul.pihlak@lhv.ee

Attachments

For LHV Group, the third quarter of 2026 was characterised by growth in income and profitability, both quarter-on-quarter and year-on-year. The strong result was driven by net interest income and fee income, as well as a larger release of loan impairments.

AS LHV Group generated consolidated net profit of EUR 37.5 million in Q3 2026, which is 52% more than in the previous quarter and 43% more than in the same period last year. Of the subsidiaries, AS LHV Pank earned a net profit of EUR 33.7 million and LHV Bank Ltd EUR 1.4 million. AS LHV Varahaldus earned a net profit of EUR 0.5 million and AS LHV Kindlustus EUR 0.3 million. The return on equity attributable to the shareholders of the Group was 19.3% in Q3.

On a consolidated basis, LHV Group generated total net income of EUR 80.1 million in Q3 2026, which is 1% more than in the previous quarter and 10% more than in the same period last year. Net interest income amounted to EUR 68.8 million (+10% quarter-on-quarter and +24% year-on-year). Growth was supported by the expansion of the loan portfolio and improved margins, with the net interest margin reaching 2.8% (Q2: 2.6%). Net fee and commission income amounted to EUR 16.8 million (+15% quarter-on-quarter and +10% year-on-year). Other income amounted to EUR -5.5 million, mainly reflecting the revaluation of the liquidity portfolio. Portfolio duration is below two years, so the loss unwinds as positions mature and in parallel generates additional interest income booked under net interest income.

Total operating expenses amounted to EUR 43.4 million, remaining at the level of the previous quarter and increasing by 12% year-on-year. Staff costs decreased by 8% quarter-on-quarter to EUR 24.1 million, while IT costs increased by 12% to EUR 5.3 million. The cost/income ratio was 54.2%. Profit before loan impairment amounted to EUR 36.7 million (+4% quarter-on-quarter and +8% year-on-year). A net release of loan impairments of EUR 8.9 million was recognised in Q3. The release came from LHV Pank and was mainly related to the release of a provision for one larger client.

As at the end of September, LHV Group’s consolidated total assets stood at EUR 10.10 billion, up 5% from the end of the previous quarter and 6% year-on-year. The consolidated loan portfolio grew by EUR 183 million, i.e. 3%, to EUR 5.95 billion in Q3 (+14% year-on-year). Deposits increased by EUR 178 million, i.e. 2%, during the quarter to EUR 7.74 billion (+4% year-on-year). The aggregate volume of funds managed by LHV grew by EUR 25 million during the quarter to EUR 1.82 billion (+12% year-on-year). Financial intermediary customers processed 24.2 million payments in Q3, a decrease of 6% compared to the previous quarter and an increase of 18% year-on-year. The number of Group customers increased by nearly 8,000 during the quarter to 723,000.

For the first nine months of the year, LHV Group generated total net income of EUR 232.8 million (+3% year-on-year), of which net interest income accounted for EUR 190.6 million (+9%) and net fee and commission income for EUR 46.1 million (+3%). Expenses grew by 14% to EUR 132.6 million. The net release of loan impairments totalled EUR 1.8 million over the nine months. Net profit amounted to EUR 81.9 million, which is 5% less than a year ago. The return on equity for the nine months was 14.0% (a year ago: 16.1%) and the cost/income ratio 57.0% (a year ago: 51.7%).

The Group’s Common Equity Tier 1 (CET1) ratio stood at 15.3% at the end of Q3, the Tier 1 capital ratio at 17.2% and the total capital adequacy ratio (CAD) at 20.3%. The liquidity coverage ratio (LCR) was 174% and the net stable funding ratio (NSFR) 146%. In August, LHV Group issued EUR 200 million of MREL bonds and EUR 15 million of AT1 bonds.

As at the end of nine months, LHV Group’s net income is falling short of the financial plan by EUR 4.5 million, while net profit exceeds the financial plan by EUR 3.6 million.

Income statement, thousands of euros   Q3 2026 Q2 2026 Q3 2025
Net interest income 68,811 62,480 55,532
Net fee and commission income 16,799 14,643 15,296
Net financial income -5,765 1,170 1,167
Result of the insurance service 219 744 627
Other operating income and expenses 60 -26 39
Total net income   80,124 79,011 72,661
Staff costs -24,072 -26,089 -22,351
Office expenses -807 -713 -730
IT costs -5,300 -4,717 -3,837
Marketing expenses -1,790 -1,059 -1,140
Other operating expenses -11,461 -11,013 -10,705
Total expenses   -43,429 -43,591 -38,763
Profit before loan impairment   36,695 35,420 33,898
Loan impairment 8,892 -5,770 -1,673
Income tax expense -8,053 -4,963 -5,916
Net profit   37,534 24,687 26,309
Minority holding 450 574 606
Profit attributable to shareholders of the parent company 37,084 24,113 25,703
         
Net profit per share, euros 0.11 0.07 0.08
Diluted net profit per share, euros 0.11 0.07 0.08
        
Balance sheet, thousands of euros   Sep 26 Jun 26 Sep 25
Cash and due from banks 3,001,723 2,760,278 3,837,093
Financial assets 1,065,486 1,058,984 402,971
Loans to customers 5,989,915 5,815,325 5,279,528
Loan impairment reserve -38,875 -47,449 -45,277
Trade receivables 41,782 29,241 12,403
Other assets 40,907 35,667 42,980
Total assets   10,100,938 9,652,047 9,529,699
Demand deposits 5,149,077 5,130,731 4,862,458
Term deposits 2,586,258 2,426,535 2,590,440
Loans received 1,232,577 1,021,079 1,048,556
Trade payables and loans received 8,967,911 8,578,345 8,501,454
Accrued expenses and other liabilities 117,143 106,273 84,143
Subordinated debt 222,295 209,215 207,001
Total liabilities   9,307,350 8,893,833 8,792,598
Owners’ equity   793,588 758,214 737,101
incl. minority holding 7,976 7,526 8,456
Total liabilities and owners’ equity   10,100,938 9,652,047 9,529,699

LHV Pank

LHV Pank’s net profit amounted to EUR 33.7 million in Q3 (+39% quarter-on-quarter and +38% year-on-year) and total net income to EUR 57.7 million (-7% quarter-on-quarter and +5% year-on-year). Net interest income grew by 11% quarter-on-quarter to EUR 59.5 million (+22% year-on-year) and net fee and commission income by 14% to EUR 13.5 million (+15% year-on-year). Expenses decreased by 5% quarter-on-quarter to EUR 26.9 million. A net release of loan impairments of EUR 10.4 million was recognised in Q3, significantly affected by the reversal of a provision on one larger corporate loan. The cost/income ratio was 46.6% (Q2: 45.3%) and return on equity 21.6% (Q2: 16.6%).

The quarter-on-quarter decrease in net income was driven by negative net financial income of EUR 10.1 million, which includes the negative effect of the liquidity portfolio and revaluation of intragroup interest rate swaps. The revaluation loss on the liquidity portfolio, which has a duration of less than two years, unwinds as the bonds mature, while the portfolio generates additional net interest income in parallel. The effect of the interest rate swaps is eliminated at the Group level. Excluding this effect, the bank’s net income amounted to EUR 61.8 million and net profit to EUR 37.9 million.

The number of LHV Pank customers increased by nearly 9,000 during the quarter to 517,000. The net loan portfolio grew by EUR 92 million during the quarter to EUR 4.91 billion (+7% year-on-year). Retail loans grew by EUR 64 million and corporate loans by EUR 28 million. The bank’s deposits increased by EUR 192 million during the quarter to EUR 6.42 billion (-3% year-on-year), of which demand deposits increased by EUR 148 million and term deposits by EUR 44 million. The increase was mainly driven by EUR 143 million growth in corporate banking deposits, while platform deposits continued to decline in line with the trend of this year.

In technology, LHV Pank took an important step in Q3 with the launch of LHV.AI, which provides a secure foundation for scaling artificial intelligence and for next-generation services for the bank’s customers. In product development, the bank launched Moneyplan, a feature that gives customers an overview of their saving habits and supports them in building regular saving. In July, the international financial magazine Euromoney recognised the bank as the Best Bank in Estonia for the seventh time. In September, the bank announced its decision to close its customer offices in Tartu and Pärnu. The decision is based on customers’ changing banking habits and the continued decline in visits to physical offices. The bank continues to invest in digital service channels, through which all main banking services are available.

For the first nine months of the year, LHV Pank generated total net income of EUR 174.0 million (+1% year-on-year) and a net profit of EUR 78.2 million (-1% year-on-year). Net income is falling short of the financial plan by EUR 8.2 million (by EUR 2.5 million excluding the revaluation effect of interest rate swaps), while net profit exceeds the plan by EUR 2.3 million (by EUR 8.1 million excluding the revaluation effect). The loan portfolio exceeds the financial plan by EUR 88 million, while deposits are EUR 340 million below plan.

LHV Bank

LHV Bank, operating in the United Kingdom, reported a net profit of EUR 1.4 million in Q3, remaining at the level of the previous quarter and up 38% year-on-year. Total net income grew by 16% quarter-on-quarter to EUR 17.1 million (+31% year-on-year) and net interest income by 10% to EUR 10.5 million (+64% year-on-year). Loan impairment charges of EUR 1.5 million were recognised in the quarter. The cost/income ratio improved to 80.4% (Q2: 85.2%).

The loan portfolio of LHV Bank grew by EUR 87 million, i.e. 9%, during the quarter to EUR 1.03 billion (+56% year-on-year). The pipeline of outstanding loan offers, approved but not yet disbursed, amounted to EUR 145 million. Deposits increased by EUR 119 million during the quarter to EUR 1.51 billion (+50% year-on-year). Direct customer deposits amounted to EUR 323 million at the end of the quarter.

For the first nine months of the year, LHV Bank’s net income grew by 17% to EUR 46.9 million, net interest income by 64% to EUR 29.3 million and net profit by 24% to EUR 4.1 million. Net interest income exceeds the financial plan by EUR 1.2 million. Net income is falling short of the plan by EUR 0.6 million and net profit by EUR 2.2 million, reflecting higher than planned loan impairments and expenses EUR 0.9 million above plan. The loan portfolio is EUR 58 million below plan and deposits are EUR 117 million below plan.

LHV Varahaldus

LHV Varahaldus earned a net profit of EUR 0.5 million in Q3 (Q2: EUR 0.4 million, Q3 2025: EUR 0.8 million). Net income grew by 2% quarter-on-quarter and by 8% year-on-year to EUR 2.5 million.

The aggregate volume of funds grew by EUR 25 million during the quarter to EUR 1.82 billion (+12% year-on-year). In Q3, the pension funds Julge, Ettevõtlik, Rahulik, Tasakaalukas and Indeks returned 1.3%, 2.2%, 0.3%, 1.1% and 1.6% respectively. At the end of the quarter, the number of Pillar II customers making active monthly contributions stood at 104,000.

For the first nine months of the year, LHV Varahaldus’s net income grew by 9% to EUR 7.3 million. Net profit amounted to EUR 0.3 million (a year earlier: EUR 1.4 million), affected by the EUR 1.1 million income tax expense associated with the dividend payment made in March. Net profit exceeds the financial plan by EUR 0.1 million, while fund volumes are EUR 14 million below plan.

LHV Kindlustus

LHV Kindlustus earned a net profit of EUR 0.3 million in Q3 (Q2: EUR 0.8 million, Q3 2025: EUR 0.7 million). Net earned premiums grew by 5% quarter-on-quarter to EUR 11.7 million (+10% year-on-year). The volume of contract premiums written amounted to EUR 11.0 million, which is 6% less than in the previous quarter and 20% more than a year ago.

Gross incurred losses increased by 15% quarter-on-quarter to EUR 8.2 million (+20% year-on-year). The net loss ratio was 72.5% (Q2: 67.9%), the net expense ratio 25.6% (Q2: 25.2%) and the combined ratio 98.1% (Q2: 93.1%). The number of customers increased by nearly 4,000 during the quarter to 246,000 (+8% year-on-year) and the number of insurance contracts stood at 337,000. The quarter was affected by several larger claims in home insurance.

For the first nine months of the year, LHV Kindlustus’s net earned premiums grew by 9% to EUR 33.3 million and gross incurred losses by 20% to EUR 23.6 million. Net profit amounted to EUR 0.4 million (a year earlier: EUR 2.4 million) and the net loss ratio was 74.0%. Net profit is falling short of the financial plan by EUR 1.7 million, mainly due to the high volume of claims at the beginning of the year. The volume of contract premiums written exceeds the financial plan by EUR 0.7 million.

Comment by Mihkel Torim, CEO of LHV Group:

“The third quarter was LHV’s strongest of the year. Net profit rose to EUR 37.5 million and return on equity to 19.3%. Our core business improved: net interest income grew 24% year on year, while costs held at the previous quarter’s level. Profit was also substantially supported by September’s release of an impairment on one large corporate loan and portfolio quality remained strong.

The loan portfolio grew by EUR 183 million in the quarter, almost half of it from LHV Bank in the UK, whose loan book passed one billion euros. The Group’s customer base reached 723,000. In August we raised EUR 200 million of MREL debt to further diversify our funding.

In Estonia we launched Moneyplan, which gives customers an overview of their spending and saving. We also went live with LHV.AI, which lets customers connect their bank account to AI tools. Positive reception of these new products confirms that we are moving in the right direction.”

AS LHV Group reports are available at: https://investor.lhv.ee/en/reports/.

To present the quarterly results, LHV Group will host a virtual investor meeting via Teams. The meeting will take place on 20 October at 11:00 AM EET. The presentation will be held in English. Please register in advance here.

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are used by over 517,000 customers, the II pillar pension funds managed by LHV have 104,000 active customers and LHV Kindlustus protects a total of 246,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises.

Investor Relations
Sten Hans Jakobsoo
Head of Investor Relations and Corporate Development
Email: stenhans.jakobsoo@lhv.ee

Communications
Paul Pihlak
Head of Communications
Email: paul.pihlak@lhv.ee

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.